Cognitive enhancement & neuroprotection peptides, cross-examined.
12 cognitive enhancement and neuroprotection peptides tracked on Peptigrity, with independent HPLC purity data, shop coverage and mechanism research for each. The category covers four mechanism classes: ACTH-derived nootropics (Semax, Selank), the sleep-regulating neuropeptide DSIP, the social and stress-modulating peptide oxytocin, and microtubule-stabilizing neuroprotective peptides (Adamax/davunetide, P21). Most compounds in this category have substantial Russian-language research bases with limited Western RCT replication.
Figures updated
How to choose between cognitive & neuroprotection peptides
Cognitive peptides target very different brain biology. Choose by the specific outcome being researched - anxiolysis without sedation, sleep architecture, social and stress modulation, or neurodegeneration models - rather than by general "nootropic" framing.
ACTH-derived nootropics
Modulation of monoamine, BDNF, and GABA pathways
Russian clinical · PreclinicalSleep-regulating peptides
Sleep architecture modulation (precise mechanism unclear)
Preclinical · Limited human dataSocial & stress modulators
Oxytocin receptor agonism, central and peripheral
Human RCT (FDA-approved indication) · Mixed (off-label)Neuroprotective peptides
Adamax (Davunetide/NAP), P21 (P021)
Microtubule stabilization, neurotrophic signaling
Preclinical · Failed Phase 3 (davunetide)Compounds in this category
Cognitive Enhancement & Neuroprotection prices →| Compound | Avg purity | Lab tests | Shops listing it |
|---|---|---|---|
Synthetic heptapeptide derived from tuftsin, researched for anxiolytic effects, immune modulation, and cognitive enhancement without sedation. | 99.6% | 338 | 448 |
Synthetic heptapeptide derived from ACTH(4-10), researched for neuroprotection, cognitive enhancement, and brain injury recovery. Approved in Russia as a nootropic. | 99.5% | 318 | 446 |
Nine-amino acid neuropeptide researched for sleep regulation, stress adaptation, and normalization of disturbed sleep architecture. | 99.3% | 247 | 398 |
| 99.1% | 65 | 243 | |
Neuroprotective octapeptide from ADNP researched for microtubule stabilization and cognitive preservation. | 99.6% | 40 | 204 |
Acetylated/amidated Semax analog (Ac-MEHFPGP-NH₂). Longer half-life than plain Semax. Distinct compound, not an alias. | 99.7% | 37 | 129 |
A seven-amino-acid analog of the natural peptide spadin — a highly selective and potent blocker of the TREK-1 potassium channel, studied in animal models for fast-onset antidepressant-like effects and enhanced hippocampal neurogenesis. | 99.7% | 12 | 84 |
| 99.5% | 10 | 136 | |
A neurotrophic peptide preparation from porcine brain — a mixture of low-molecular-weight peptides and free amino acids mimicking the body's own neurotrophic factors, used for stroke, TBI, and dementia in many countries (though not FDA-approved). | 99.7% | 5 | 64 |
An angiotensin IV-derived peptidomimetic engineered for blood-brain-barrier penetration and oral activity, researched for its ability to potentiate hepatocyte growth factor (HGF)/c-Met signaling and drive hippocampal synapse formation. | 99.8% | 1 | 72 |
| No lab tests yet · 2 compounds | |||
A 15-amino-acid peptide derived from the FG loop of the neural cell adhesion molecule (NCAM) — a mimetic that activates the fibroblast growth factor receptor (FGFR1) to promote synapse formation, neurogenesis, and memory in preclinical models. | — | Submit one → | 5 |
A synthetic nootropic dipeptide (INN omberacetam) developed in Russia — a prodrug of the endogenous neuropeptide cycloprolylglycine that enhances cognition and neuroprotection at doses roughly 1,000× lower than piracetam. | — | Submit one → | 21 |
Lab tests link to each compound's lab-test page. Purity dots: ≥98% green · 95–98% purple · 90–95% amber · under 90% red (the /lab-tests bands). “Shops listing it” counts shops that list the compound, tested or not.
Mechanism overview
Semax and Selank are both ACTH-pathway peptides - Semax derived from the ACTH 4-10 fragment, Selank from tuftsin, an immunoregulatory tetrapeptide. Despite different parent sequences, both modulate monoamine neurotransmission (serotonin, dopamine, norepinephrine) and brain-derived neurotrophic factor (BDNF) expression. Selank additionally influences GABA receptor function, which underlies its anxiolytic-without-sedation profile. The two compounds are sometimes researched as a stack for combined nootropic and anxiolytic effect.
DSIP's mechanism is the least-characterized in this category. The compound crosses the blood-brain barrier and modulates sleep EEG patterns in animal models, but the receptor target - if there is a single canonical target - has not been identified. Research has documented effects on slow-wave sleep duration, stress-induced sleep disruption, and circadian rhythm normalization. The mechanism question remains open after four decades of research.
Oxytocin's peripheral receptor (OXTR) is well-characterized; the central nervous system pharmacology is more complex. Endogenous oxytocin neurons project from the paraventricular and supraoptic nuclei to multiple brain regions, with effects on social behavior, stress reactivity, and attachment. Exogenous intranasal oxytocin reaches some central regions in small studies, but the relationship between intranasal dose and central nervous system concentration is heavily debated in the research literature.
The neuroprotective peptides operate on different biology entirely. Davunetide stabilizes microtubules through interaction with the tau protein, with research interest in tauopathies (Alzheimer's, progressive supranuclear palsy, frontotemporal dementia). P21 mimics the active region of CNTF, activating neurotrophic signaling pathways implicated in neuron survival and synaptogenesis. Both are research compounds in early-stage neuroscience rather than translation-ready therapeutics.
For deeper background on peptide pharmacology, see how peptides are made.
⚠ Quality verification: cognitive peptides have category-specific risks
Cognitive peptides have a distinct verification dimension because most are administered intranasally rather than by injection.
INTRANASAL FORMULATION QUALITY: Intranasal peptides require sterile preparation appropriate for mucosal contact. Unlike injection, where endotoxin testing is critical, intranasal administration tolerates somewhat higher microbial burden - but pH, osmolality, and preservative content matter for nasal mucosa health. Vendor preparation standards vary widely.
SHORT PEPTIDE IDENTITY SUBSTITUTION: Semax (7 amino acids) and Selank (7 amino acids) are short peptides easily mis-synthesized or substituted. Mass spectrometry molecular-weight verification is essential - both peptides have specific MW signatures that confirm correct sequence.
OXYTOCIN POTENCY DEGRADATION: Oxytocin is unusually labile and degrades quickly under suboptimal storage. Lab tests on aged or improperly stored oxytocin show substantial degradation product peaks. Recent CoA dates matter more for oxytocin than for most peptides.
DAVUNETIDE / P21 LIMITED VERIFICATION: These compounds have very thin shop coverage on Peptigrity. Independent test data is sparse, meaning buyer trust must rest more on vendor reputation than on third-party verification.
Frequently asked questions
One - partially. Oxytocin is FDA-approved as Pitocin for labor induction, but not for cognitive or social applications, which are off-label uses. Semax and Selank are approved as nootropic drugs in the Russian Federation but not in Western jurisdictions. DSIP, Adamax (davunetide), and P21 have no regulatory approval anywhere; all are research compounds. The Russian clinical research base for Semax and Selank is substantial but has not been replicated through Western controlled trials sufficient to support FDA approval.
Different parent sequences, different primary effects. Semax (derived from ACTH 4-10) is researched primarily as a nootropic - attention, cognitive performance, recovery after ischemic events. Selank (derived from tuftsin) is researched primarily as an anxiolytic - anxiety reduction without the sedation, cognitive impairment, or dependence associated with benzodiazepines. Both modulate BDNF and monoamine systems, but Selank's GABA pathway involvement explains its anxiolytic-specific profile. The two are sometimes researched as a stack rather than as alternatives.
Most cognitive peptides in this category are administered intranasally rather than by injection - Semax, Selank, and oxytocin all have established intranasal research protocols, and intranasal delivery may have favorable blood-brain barrier penetration for some compounds. DSIP, Adamax, and P21 are typically administered by injection in research contexts. Intranasal administration has different concentration, dosing, and quality requirements than injection - verify the vendor's preparation is appropriate for the intended route.
Both compounds were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences - Semax in the 1980s, Selank in the 1990s. Both are approved nootropic drugs in the Russian Federation with substantial post-marketing clinical data published in Russian-language medical journals. Western pharmaceutical companies have not pursued development for FDA approval, partly because the existing Russian patent and regulatory landscape makes Western IP protection difficult. The replication gap between Russian and Western research is similar to the situation with Khavinson bioregulators - substantial evidence exists, but in a different language and regulatory tradition than Western buyers typically encounter.
Yes, in its original formulation. Davunetide (also known as NAP, AL-108, or AL-208) reached Phase 2 and Phase 3 trials for progressive supranuclear palsy, sponsored by Allon Therapeutics. The Phase 3 trial did not meet its primary endpoint, and the program was discontinued in 2012. The compound continues in preclinical and early-stage research for related neurodegenerative conditions, but no active Phase 3 program is currently running. Buyers should treat Adamax/davunetide as an early-stage research compound rather than a near-clinical-translation peptide.
Limited research exists on interactions between cognitive peptides and prescription medications. Selank's GABA pathway activity has theoretical interaction potential with benzodiazepines and other GABAergic drugs. Semax's monoamine effects have theoretical interaction potential with antidepressants and stimulants. Oxytocin has documented interactions with psychiatric medications. None of these interactions have been characterized in formal clinical trials. Anyone taking prescription medications should consult a healthcare provider before researching peptide combinations. The general absence of formal interaction studies is a research-context risk for this entire category.
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.